MTA1 and prostate carcinoma: Li et al. had identified MTA1 as a tumor-associated antigen in 2008 using the serological analysis of recombinant cDNA expression libraries (SEREX) approach [37] and found that MTA1 has a cancer-related serological profile only reacting with the serum from prostate cancer patients but not with that from any of the healthy donors tested (0/13), suggesting the presence of a natural MTA1-specific humoral immune response.